Blockchain Registration Transaction Record

VolitionRx Highlights Sepsis Biomarker Breakthrough with Nu.Q NETs Assay

VolitionRx Limited highlights growing evidence for its Nu.Q NETs assay as a sepsis biomarker. The test distinguishes sepsis from inflammation and predicts outcomes. Learn how this low-cost blood test could personalize patient care.

Sepsis is a life-threatening condition that affects millions worldwide, often leading to organ failure and death. Current diagnostic challenges include distinguishing sepsis from non-infectious inflammation and predicting patient outcomes. VolitionRx's Nu.Q NETs assay offers a low-cost, rapid blood test that could transform sepsis management by enabling early detection, personalized treatment, and improved survival rates. This innovation matters because it addresses a critical unmet need in critical care, potentially saving lives and reducing healthcare costs.